-
EP1549387
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP1549387
| EP1549387 - ANTISENSE MODULATION OF FARNESOID X RECEPTOR EXPRESSION [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 07.09.2007 Database last updated on 30.10.2024 | Most recent event Tooltip | 12.09.2008 | Change - representative | published on 15.10.2008 [2008/42] | Applicant(s) | For all designated states Pharmacia Corporation 100 Route 206 North Peapack, NJ 07977 / US | [2007/15] |
| Former [2005/27] | For all designated states Pharmacia Corporation 700 Chesterfield Parkway West Chesterfield, MO 63017-1732 / US | Inventor(s) | 01 /
KANE, Christopher, D. 1056 Del Ebro Drive Ballwin, MO 63011 / US | [2005/27] | Representative(s) | Hirsch, Denise Marie Pfizer European Pharma Patent Department 23-25. Avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | [N/P] |
| Former [2008/42] | Hirsch, Denise Marie Pfizer European Pharma Patent Department 23-25. avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | ||
| Former [2005/27] | Hirsch, Denise Marie Pfizer European Pharma Patent Department 23-25, avenue du Docteur Lannelongue 75668 Paris Cedex 14 / FR | Application number, filing date | 03776193.9 | 25.09.2003 | [2005/27] | WO2003US30353 | Priority number, date | US20020413588P | 25.09.2002 Original published format: US 413588 P | [2005/27] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2004030750 | Date: | 15.04.2004 | Language: | EN | [2004/16] | Type: | A1 Application with search report | No.: | EP1549387 | Date: | 06.07.2005 | Language: | EN | The application published by WIPO in one of the EPO official languages on 15.04.2004 takes the place of the publication of the European patent application. | [2005/27] | Search report(s) | International search report - published on: | US | 15.04.2004 | Classification | IPC: | A61N1/05 | [2005/27] | CPC: |
C07F9/65586 (EP,US);
A61P3/04 (EP);
A61P3/06 (EP);
A61P3/10 (EP);
A61P37/02 (EP);
A61P9/02 (EP);
A61P9/10 (EP);
C07F9/65616 (EP,US);
C12N15/1138 (EP,US);
A61K38/00 (EP,US);
C12N2310/315 (EP,US);
C12N2310/321 (EP,US);
C12N2310/3341 (EP,US);
C12N2310/341 (EP,US);
C12N2310/346 (EP,US);
Y02P20/582 (EP,US)
(-)
| C-Set: |
C12N2310/321, C12N2310/3521 (EP,US);
C12N2310/321, C12N2310/3525 (US,EP) | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LI, LU, MC, NL, PT, RO, SE, SI, SK, TR [2005/27] | Extension states | AL | Not yet paid | LT | Not yet paid | LV | Not yet paid | MK | Not yet paid | Title | German: | ANTISENSE-MODULIERUNG DER FARNESOID-X-REZEPTOR-EXPRESSION | [2005/27] | English: | ANTISENSE MODULATION OF FARNESOID X RECEPTOR EXPRESSION | [2005/27] | French: | MODULATION ANTISENS DE L'EXPRESSION DU FXR (FARNESOID X RECEPTOR) | [2005/27] | Entry into regional phase | 25.04.2005 | National basic fee paid | 25.04.2005 | Search fee paid | 25.04.2005 | Designation fee(s) paid | 25.04.2005 | Examination fee paid | Examination procedure | 22.04.2004 | Request for preliminary examination filed International Preliminary Examining Authority: US | 25.04.2005 | Examination requested [2005/27] | 10.06.2005 | Amendment by applicant (claims and/or description) | 03.04.2007 | Application deemed to be withdrawn, date of legal effect [2007/41] | 09.05.2007 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2007/41] | Fees paid | Renewal fee | 30.09.2005 | Renewal fee patent year 03 | Penalty fee | Additional fee for renewal fee | 30.09.2006 | 04 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [ ] - No relevant documents have been disclosed. |